Breaking News
Investing Pro 0
Black Friday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)

May 25, 2022 09:18
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

 

 
NDX
-0.70%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
INTU
-0.85%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JWN
+2.03%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
A
+1.04%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
OSUR
+0.40%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CAL
-1.21%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Pre-Open Stock Movers:

Verrica Pharmaceuticals Inc. (Nasdaq: NASDAQ:VRCA) 54% LOWER; announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).

Elevation Oncology, Inc. (Nasdaq: ELEV) 16% HIGHER; The FDA has granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. Seribantumab is currently being evaluated in the ongoing Phase 2 CRESTONE study, for which initial data will be presented in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting on Tuesday, June 7, 2022.

Express (EXPR) 11% HIGHER; reported Q1 EPS of ($0.10), $0.05 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $450.8 million versus the consensus estimate of $435.74 million. Express sees FY2022 EPS of $0.14-$0.20, versus the consensus of $0.17.

Caleres (NYSE:CAL) 10% HIGHER; reported Q1 EPS of $1.32, $0.49 better than the analyst estimate of $0.83. Revenue for the quarter came in at $735.1 million versus the consensus estimate of $677.28 million. The company now expects consolidated sales levels to be up between 2 percent and 5 percent when compared to fiscal year 2021 and expects earnings per diluted share to be between $4.20 and $4.40, representing another year of record or near-record earnings for the organization.

Wendy's (NASDAQ:WEN) 9% HIGHER; long-time shareholder Nelson Peltz of Trian Fund Management said they are exploring a potential transaction, including a possible merger.

OraSure Technologies, Inc. (OSUR) 7% HIGHER; announced today that its InteliSwab® COVID-19 Rapid Test has been selected by the U.S. Department of Health and Human Services (HHS) to be distributed to schools nationwide. The HHS program provides school districts with at-home COVID-19 test kits to be sent home with students, teachers and staff to help keep the nations schools safe as the pandemic continues. Tests provided under this program will be funded as part of OraSures procurement contract from the Defense Logistics Agency.

Chinook Therapeutics, Inc. (Nasdaq: KDNY) 7% LOWER; commenced an underwritten public offering of its common stock,

2U, Inc. (NASDAQ:TWOU) 5% LOWER; Piper Sandler analyst Arvind Ramnani downgraded from Neutral to Underweight with a price target of $9.00 (from $10.00).

Nordstrom (NYSE:JWN) 4% HIGHER; reported Q1 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $3.57 billion versus the consensus estimate of $3.27 billion. Nordstrom sees FY2022 EPS of $3.20-$3.50, versus the consensus of $3.12.

Toll Brothers (NYSE:TOL) 3% HIGHER; reported Q2 EPS of $1.85, $0.31 better than the analyst estimate of $1.54. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.06 billion. Backlog value was $11.7 billion at second quarter end, up 35% compared to FY 2021’s second quarter; homes in backlog were 11,768, up 16%.

Intuit (NASDAQ:INTU) 2% HIGHER; reported Q3 EPS of $7.65, $0.07 better than the analyst estimate of $7.58. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.51 billion. Intuit sees FY2022 EPS of $11.68-$11.74, versus the consensus of $11.66. Intuit sees FY2022 revenue of $12.633-12.674 billion, versus the consensus of $12.32 billion.

Trevi Therapeutics (NASDAQ:TRVI) 3% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $10.

Agilent Technologies (NYSE:A) 1% HIGHER; reported Q2 EPS of $1.13, $0.09 better than the analyst estimate of $1.04. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.5 billion. Agilent Technologies sees Q3 2022 EPS of $1.20-$1.22, versus the consensus of $1.12. Agilent Technologies sees Q3 2022 revenue of $1.625-1.65 billion, versus the consensus of $1.56 billion.

Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
 

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email